<SEC-DOCUMENT>0001193125-25-121049.txt : 20250516
<SEC-HEADER>0001193125-25-121049.hdr.sgml : 20250516
<ACCEPTANCE-DATETIME>20250515200116
ACCESSION NUMBER:		0001193125-25-121049
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250515
FILED AS OF DATE:		20250516
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		25956601

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d947676d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as May 15, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d947676dex991.htm">Immutep&#146;s Efti with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) &amp; Chemotherapy
Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May 15, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d947676dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g947676g21i59.jpg" ALT="LOGO" STYLE="width:2.41042in;height:0.763194in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) &amp; Chemotherapy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Achieves High Response Rates in First-Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Notably, ~92% of all evaluable patients have <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS &lt;50%, including
43% with <FONT STYLE="white-space:nowrap">PD-L1</FONT> below 1 (TPS &lt;1%), who represent an area of high unmet need </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data demonstrates significant improvement in response rates compared to historical controls, and safety continues
to be favourable </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multi-centre <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is evaluating the same
immunotherapy/chemotherapy combination used in the pivotal <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III in 1L NSCLC </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is planned for presentation at a medical
conference later this year </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; May</B><B></B><B>&nbsp;15, </B><B>2025 &#150;</B> <U>Immutep Limited</U> (ASX:
IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has
been achieved in the investigator-initiated <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial as of the data-cut off date of 06 May 2025. <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is evaluating eftilagimod alpha (efti) in
combination with the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and doublet chemotherapy as first-line
treatment for patients with advanced or metastatic <FONT STYLE="white-space:nowrap">non-squamous</FONT> <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marc Voigt, CEO of Immutep, stated</B>, &#147;Our level of confidence in efti driving a new standard of care for patients with <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer via our pivotal <FONT STYLE="white-space:nowrap">TACTI-004</FONT> trial continues to rise with the strength of the data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> and <FONT
STYLE="white-space:nowrap">TACTI-002.</FONT> Across two trials we have now efficacy data from 165 patients with 1L NSCLC who have been treated with efti and KEYTRUDA, either with or without chemotherapy. In multi-national settings, efti has
generated consistent and remarkable improvements in response rates. In particular, the interim ORR data in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression below 50% in the ongoing
<FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial, who represent over <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the 1L NSCLC patient population, is very encouraging.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Majority of Patients have <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS &lt;50% </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, ~92% of all evaluable patients (N=51) in the <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> study have
<FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS &lt;50%. This includes 49% of patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) of <FONT STYLE="white-space:nowrap">1-49%</FONT> and 43% of patients with <FONT
STYLE="white-space:nowrap">PD-L1</FONT> TPS &lt;1%, as shown in the table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strong Response Rates Across All
<FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression Levels </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from all evaluable patients demonstrates significant improvement of Overall
Response Rate (ORR) according to RECIST 1.1 across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression compared to historical control from a registrational trial of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and doublet chemotherapy in <FONT STYLE="white-space:nowrap">non-squamous</FONT> 1L NSCLC<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">75.0% ORR versus 62.1% ORR in patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (TPS
<U>&gt;</U>50%) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">64.0% ORR versus 49.2% ORR in patients with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (TPS <FONT
STYLE="white-space:nowrap">1-49%)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54.5% ORR versus 32.3% ORR in patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression
(TPS &lt;1%) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 60.8% response rate regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (TPS <FONT
STYLE="white-space:nowrap">0-100%)</FONT> represents a substantial improvement compared to historical control of 48.0%.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;The relative outperformance is particularly strong given the
registrational trial has four times as many patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (~32% of patients versus ~8% in <FONT STYLE="white-space:nowrap">INSIGHT-003),</FONT> who have the highest response rates. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g947676g21i59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</DIV>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, in patients with TPS &lt;50% (N=47), who have a high unmet need and represent over <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the 1L NSCLC patient populaton, the triple combination with efti achieved a 59.6% response rate as compared to historical control of 40.8%.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="20" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> Overall Response Rate&nbsp;&amp; Disease Control Rate, according to RECIST1.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression
Levels</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">TPS&nbsp;0-100%</FONT><BR>(N=51)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TPS&nbsp;&lt;1%</B><br><B>(N=22)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">TPS&nbsp;1-49%</FONT></B><br><B>(N=25)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TPS&nbsp;&lt;50%</B><br><B>(N=47)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TPS&nbsp;</B>&#8805;<B></B><B>50%</B><br><B>(N=4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ORR%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DCR%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Safety continues
to be favourable for the triple combination in 1L NSCLC with no new safety signals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional data updates from this trial are expected to be presented at a medical conference in 2025 and beyond. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated study conducted by the <U>Frankfurt Institute of Clinical Cancer Research
IKF</U> and several other German centres. It is being run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple combination therapy in
front-line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients consisting of efti administered subcutaneously in conjunction with an existing approved
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy (pembrolizumab) and chemotherapy
(carboplatin and pemetrexed) delivered intravenously. The trial will assess the safety, tolerability, and initial efficacy of the combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Eftilagimod Alfa (efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist
that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major
histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological
molecules like <FONT STYLE="white-space:nowrap">IFN-&#436;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is
under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables
various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC
from the United States Food and Drug Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g947676g21i59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</DIV>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding
and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses
<FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for
shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Shirish Gadgeel et al., Updated Analysis From <FONT STYLE="white-space:nowrap">KEYNOTE-189:</FONT>
Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non&#150;Small-Cell Lung Cancer. JCO 38, 1505-1517(2020). DOI:10.1200/JCO.19.03136 </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck<SUB
STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>catherine.strong@sodali.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g947676g21i59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g947676g21i59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^$TSX7UX^-C?8Q!]I\SS_,'W,],9STXQ72>F>C 8&* "@ H * "@ H * "@
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ME@V?YT =QX0\0W/B"UN9;F.*-HG"@1@CMGN: '^)?%=OX>5(S&9KF096,'
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M-]Z6.%S]25H ROABJF34B0#@1_\ LU '6>(-"L]6TV=)($\\(3'(%&Y3VYH
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M?"EAL.=JE3[$,: -X]"* /"KNS33M<DM+L,8HIMK[>"5SU'X4 >C0> O#]S
MDT+SO&X#*PEX(_*@!Y^'FA#_ )^/^_O_ -:@!WC*VCL_ TEM%GRXA&BYZX#
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M ,'[,UQH^BVYW(<(<@<H1$Q!_ XH ="EW)?V5Y>1[)3(T0C'(1=C$G\2!^E
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MYH I>.8WD\)W*1HSL63 49/WA0!A?#2"6%]2\V)X\B/&Y2,_>H ] H * "@
&H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
